Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,477JPY
17 Jan 2017
Change (% chg)

¥-89 (-1.36%)
Prev Close
¥6,566
Open
¥6,601
Day's High
¥6,609
Day's Low
¥6,477
Volume
649,200
Avg. Vol
982,044
52-wk High
¥7,929
52-wk Low
¥5,366

Select another date:

Thu, Nov 17 2016

BRIEF-Eisai Co says FDA grants fast track designation for development of E2609

* Eisai inc - first phase 3 study for e2609 in clinical trial program will enroll 1,330 patients with biomarkers confirmed for early alzheimer's disease

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

Eisai latest cancer drugmaker to win UK approval after price cut

LONDON, Nov 3 Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.

BRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial

* Eisai and Halozyme initiate Phase 1b/2 clinical trial with first patient dosing of eribulin in combination with PEGPH20 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Select another date: